Sickle Cell RetinopathyRAVOSNCT06396403
The Role of Red Cell Characteristics, Angiogenesis, Viscosity and Oxygenation in the Pathophysiology of Sickle Cell Related Retinopathy
An observational study of Sickle Cell Retinopathy and Sickle Cell Disease, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 1 site in Netherlands.
Trial summary
Objective: to gain insight in the pathogenesis, to identify biomarkers to recognize patients at risk for proliferative SCR and to investigate its associations with clinical and laboratory characteristics. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Sickle Cell Retinopathy, Sickle Cell Disease, Sickle Cell SC Disease
- What is being tested?
- Collection of venous blood samples
- How many people
- 68 participants
- Where
- 1 siteNetherlands
- Study dates
- 13 Jun 2023to 17 Jun 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients with sickle cell disease (SCD) with the HbSS or HbSC genotype, attending the outpatient Sickle Cell Clinic from the Amsterdam UMC.
Who may be able to join
- Minimum age of 18 years
- HbSC or HbSS genotype
- Recent ophthalmologic examination (up to 2 years prior) or (willingness to attend) upcoming examination
Who cannot join
- Age below 18 years
- Genotype other than HbSC or HbSS
- No recent ophthalmologic examination and no intention to visit the outpatient clinic for ophthalmic and hematologic examination
- Participation in trials with either crizanlizumab, voxelotor or mitapivat.
Trial locations and contacts
1 site in 1 country.
About this study
Objective:
to gain insight in the pathogenesis, to identify biomarkers to recognize patients at risk for proliferative SCR and to investigate its associations with clinical and laboratory characteristics.
Endpoints:
The investigators will determine the difference in the above named parameters between patients with and without PSCR
Study design:
This case control study will include adult sickle cell disease patients with the HbSS or HbSC genotype. For both genotypes, 20 patients without sickle cell retinopathy (SCR) and 20 patients with PSCR will be included, resulting in a total of 80 patients. Venous blood samples and retinal imaging scans will be collected for each included patient.
Read the detailed description
Rationale:
Sickle cell disease (SCD) is characterized by chronic hemolysis and recurrent microvascular occlusion, resulting in ischemia and organ damage1. This study focuses on retinal damage: sickle cell retinopathy (SCR). SCR results from ischemic vascular disease and secondary angiogenesis, but it is unknown which factors play a significant role in the pathogenesis. Studies on this subject are still in an early phase3,4. Our aim is to gain insight in the pathogenesis, to identify biomarkers to recognize patients at risk for proliferative SCR and to investigate its associations with clinical and laboratory characteristics. The focus of our study is aimed at evaluation of innovative biomarkers of angiogenesis, whole blood viscosity and innovative characterization of red blood cell parameters such as deformability, adhesiveness and "point of sickling" as can be measured ex vivo by the Oxygenscan (i.e.: red cell sickling capacity). The Oxygenscan is a new method to calculate the deformability of red blood cells as a function of the partial pressure of oxygen. These novel parameters will be related to clinical characteristics observed in these patients and specific markers of early retinopathy such as vessel density and macula thinning assessed by OCT angiography.
Objective:
The objective of this study is to gain insight in the pathogenesis, to identify the role of red cell characteristics, markers of angiogenesis, retinal oxygenation and whole blood viscosity in the development of proliferative SCR and to investigate its associations with clinical and laboratory characteristics.
Study design:
Case control study
Study population:
Adult patients with sickle cell disease (SCD) with a HbSS or HbSC genotype. For both genotypes, 20 patients without SCR and 20 patients with proliferative SCR will be included. The total amount of included patients will be 80 patients.
Intervention:
venous blood samples (1 EDTA tube and 1 PECT tubes of 4-5 mL each) will be collected from all included patients, who will be requested to fast 8 hours before the collection of blood. If fasting is not desired/possible, a low-fat breakfast can be consumed.
Main study parameters/endpoints: (1) The difference in red blood cell characteristics (point of sickling) between patients with and without PSCR, (2) The difference in plasma levels of parameters representing the level of systemic angiogenesis activity (CD105, VEGF, CTGF and angiopoietin-2) between patients with and without PSCR, (3) The difference in oxygenation of the retina by assessing the vessel density with angio-OCT and by assessing the oxygen saturation in the retinal arterioles and venules with the Oxymap scan in patients with and without PSCR, (4) The difference in whole blood viscosity between patients with and without PSCR
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
Data from recent ophthalmologic and hematologic examinations will be collected. If no recent ophthalmologic examination is available and no further appointments were made yet, the patient will be contacted to visit the outpatient clinic for a new appointment. Since the appointments are in accordance with the general screening schedule according to the Dutch Guidelines for Sickle Cell Disease, these investigations are no extra burden for the patients. Venous blood samples will be obtained by venepuncture, preferably during the routine venepuncture for scheduled hematological visits (so the only extra burden consists of the extra blood aliquots that have be drawn to answer the research questions). Venepuncture is a safe and frequently used procedure in the routine care of patients with sickle cell disease. Due to the request to fast before the venepuncture, appointments will only be scheduled in the morning in order to reduce the burden on the patient as much as possible.
- Conditions
- Sickle Cell Retinopathy, Sickle Cell Disease, Sickle Cell SC Disease, Sickle Cell-SS Disease
- Being tested
- Collection of venous blood samples
- Medical subject headings
- Anemia, Sickle Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Collection of venous blood samplesOther
collection includes 1 EDTA tube and 1 Sarstedt S-Monovette tube of 5 mL
| Study group | Role | What they receive |
|---|---|---|
| HbSS patients without SCR | Adult sickle cell patients with the HbSS genotype and without sickle cell retinopathy Receives: Other: Collection of venous blood samples | |
| HbSS patients with PSCR | Adult sickle cell patients with the HbSS genotype and proliferative sickle cell retinopathy Receives: Other: Collection of venous blood samples | |
| HbSC patients without SCR | Adult sickle cell patients with the HbSC genotype and without sickle cell retinopathy Receives: Other: Collection of venous blood samples | |
| HbSC patients with PSCR | Adult sickle cell patients with the HbSC genotype and proliferative sickle cell retinopathy Receives: Other: Collection of venous blood samples |
What is being measured
The primary outcome is the main question the study is designed to answer.
Differences in Red blood cell characteristics (Oxygenscan)
The difference in red blood cell characteristics (point of sickling) between patients with and without PSCR in both genotypes
Measured: Immediately after the venepuncture
Differences in Angiogenesis biomarkers
The difference in plasma levels of parameters representing the level of systemic angiogenesis activity (CD105, VEGF, CTGF and angiopoietin-2) between patients with and without PSCR in both genotypes
Measured: Immediately after the venepuncture
Differences in Retinal Oxygenation
The difference in oxygenation of the retina by assessing the vessel density with angio- OCT and by assessing the oxygen saturation in the retinal arterioles and venules with the Oxymap scan in patients with and without PSCR in both genotypes
Measured: Immediately after the venepuncture
Differences in Whole blood viscosity
The difference in whole blood viscosity between patients with and without PSCR in both genotypes
Measured: Immediately after the venepuncture
Secondary outcomes (4)
Associations between Oxygenation parameters and Red blood cell characteristics
Association between retinal vessel density assessed by OCT-angiography, oxygen saturation assessed by an Oxymap scan and red blood cell characteristics (deformity, adhesion and point of sickling upon hypoxia)
Measured: Immediately after the venepuncture
Associations between sex, age, and genotype and the biomarkers of angiogenesis
Association between sex, age, and genotype and the biomarkers of angiogenesis
Measured: Immediately after the venepuncture
Association between hemoglobin, and HbF and biomarkers of angiogenesis
Association between hemoglobin, and HbF and biomarkers of angiogenesis
Measured: Immediately after the venepuncture
Associations between whole blood viscosity and genotype
Associations between whole blood viscosity and genotype
Measured: Immediately after the venepuncture
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 May 2024
- Study start13 Jun 2023
- Primary completion17 Jun 2024
- Study completion17 Jun 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sickle Cell RetinopathyStudies of the same condition, open and under way.
- More trials run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 68 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Bart J. Biemond, Amsterdam UMC, location AMC
- Investigators
- Bart J Biemond, MD PhD, Principal investigator, Department of Hematology, Amsterdam UMC, Amsterdam, The Netherlands
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06396403
- Sponsor's protocol ID
- NL81111.018.22
- Acronym
- RAVOS
- Status last verified
- Nov 2024
- First submitted
- 24 Apr 2024
- Last updated
- 15 Nov 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role of Red Cell Characteristics, Angiogenesis, Viscosity and Oxygenation in the Pathophysiology of Sickle Cell Related Retinopathy
- ClinicalTrials.gov ID
- NCT06396403
- Acronym / sponsor ID
- RAVOS / NL81111.018.22
- Conditions
- Sickle Cell Retinopathy, Sickle Cell Disease, Sickle Cell SC Disease, Sickle Cell-SS Disease
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 68 participants (actual)
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)University, hospital or other
- Study start
- 13 Jun 2023 (actual)
- Primary completion
- 17 Jun 2024 (actual)
- Study completion
- 17 Jun 2024 (actual)
- First posted
- 2 May 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objective:
to gain insight in the pathogenesis, to identify biomarkers to recognize patients at risk for proliferative SCR and to investigate its associations with clinical and laboratory characteristics.
Endpoints:
The investigators will determine the difference in the above named parameters between patients with and without PSCR
Study design:
This case control study will include adult sickle cell disease patients with the HbSS or HbSC genotype. For both genotypes, 20 patients without sickle cell retinopathy (SCR) and 20 patients with PSCR will be included, resulting in a total of 80 patients. Venous blood samples and retinal imaging scans will be collected for each included patient.
Detailed description
Rationale:
Sickle cell disease (SCD) is characterized by chronic hemolysis and recurrent microvascular occlusion, resulting in ischemia and organ damage1. This study focuses on retinal damage: sickle cell retinopathy (SCR). SCR results from ischemic vascular disease and secondary angiogenesis, but it is unknown which factors play a significant role in the pathogenesis. Studies on this subject are still in an early phase3,4. Our aim is to gain insight in the pathogenesis, to identify biomarkers to recognize patients at risk for proliferative SCR and to investigate its associations with clinical and laboratory characteristics. The focus of our study is aimed at evaluation of innovative biomarkers of angiogenesis, whole blood viscosity and innovative characterization of red blood cell parameters such as deformability, adhesiveness and "point of sickling" as can be measured ex vivo by the Oxygenscan (i.e.: red cell sickling capacity). The Oxygenscan is a new method to calculate the deformability of red blood cells as a function of the partial pressure of oxygen. These novel parameters will be related to clinical characteristics observed in these patients and specific markers of early retinopathy such as vessel density and macula thinning assessed by OCT angiography.
Objective:
The objective of this study is to gain insight in the pathogenesis, to identify the role of red cell characteristics, markers of angiogenesis, retinal oxygenation and whole blood viscosity in the development of proliferative SCR and to investigate its associations with clinical and laboratory characteristics.
Study design:
Case control study
Study population:
Adult patients with sickle cell disease (SCD) with a HbSS or HbSC genotype. For both genotypes, 20 patients without SCR and 20 patients with proliferative SCR will be included. The total amount of included patients will be 80 patients.
Intervention:
venous blood samples (1 EDTA tube and 1 PECT tubes of 4-5 mL each) will be collected from all included patients, who will be requested to fast 8 hours before the collection of blood. If fasting is not desired/possible, a low-fat breakfast can be consumed.
Main study parameters/endpoints: (1) The difference in red blood cell characteristics (point of sickling) between patients with and without PSCR, (2) The difference in plasma levels of parameters representing the level of systemic angiogenesis activity (CD105, VEGF, CTGF and angiopoietin-2) between patients with and without PSCR, (3) The difference in oxygenation of the retina by assessing the vessel density with angio-OCT and by assessing the oxygen saturation in the retinal arterioles and venules with the Oxymap scan in patients with and without PSCR, (4) The difference in whole blood viscosity between patients with and without PSCR
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
Data from recent ophthalmologic and hematologic examinations will be collected. If no recent ophthalmologic examination is available and no further appointments were made yet, the patient will be contacted to visit the outpatient clinic for a new appointment. Since the appointments are in accordance with the general screening schedule according to the Dutch Guidelines for Sickle Cell Disease, these investigations are no extra burden for the patients. Venous blood samples will be obtained by venepuncture, preferably during the routine venepuncture for scheduled hematological visits (so the only extra burden consists of the extra blood aliquots that have be drawn to answer the research questions). Venepuncture is a safe and frequently used procedure in the routine care of patients with sickle cell disease. Due to the request to fast before the venepuncture, appointments will only be scheduled in the morning in order to reduce the burden on the patient as much as possible.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| HbSS patients without SCR | – | Other: Collection of venous blood samplesAdult sickle cell patients with the HbSS genotype and without sickle cell retinopathy |
| HbSS patients with PSCR | – | Other: Collection of venous blood samplesAdult sickle cell patients with the HbSS genotype and proliferative sickle cell retinopathy |
| HbSC patients without SCR | – | Other: Collection of venous blood samplesAdult sickle cell patients with the HbSC genotype and without sickle cell retinopathy |
| HbSC patients with PSCR | – | Other: Collection of venous blood samplesAdult sickle cell patients with the HbSC genotype and proliferative sickle cell retinopathy |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients with sickle cell disease (SCD) with the HbSS or HbSC genotype, attending the outpatient Sickle Cell Clinic from the Amsterdam UMC.
Key inclusion criteria (3 listed)
- Minimum age of 18 years
- HbSC or HbSS genotype
- Recent ophthalmologic examination (up to 2 years prior) or (willingness to attend) upcoming examination
Key exclusion criteria (4 listed)
- Age below 18 years
- Genotype other than HbSC or HbSS
- No recent ophthalmologic examination and no intention to visit the outpatient clinic for ophthalmic and hematologic examination
- Participation in trials with either crizanlizumab, voxelotor or mitapivat.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Collection of venous blood samplescollection includes 1 EDTA tube and 1 Sarstedt S-Monovette tube of 5 mL | Other | HbSC patients with PSCR, HbSC patients without SCR, HbSS patients with PSCR, HbSS patients without SCR |
Primary outcome
Differences in Red blood cell characteristics (Oxygenscan)
Time frame: Immediately after the venepuncture
The difference in red blood cell characteristics (point of sickling) between patients with and without PSCR in both genotypes
Differences in Angiogenesis biomarkers
Time frame: Immediately after the venepuncture
The difference in plasma levels of parameters representing the level of systemic angiogenesis activity (CD105, VEGF, CTGF and angiopoietin-2) between patients with and without PSCR in both genotypes
Differences in Retinal Oxygenation
Time frame: Immediately after the venepuncture
The difference in oxygenation of the retina by assessing the vessel density with angio- OCT and by assessing the oxygen saturation in the retinal arterioles and venules with the Oxymap scan in patients with and without PSCR in both genotypes
Differences in Whole blood viscosity
Time frame: Immediately after the venepuncture
The difference in whole blood viscosity between patients with and without PSCR in both genotypes
4 secondary outcomes
Associations between Oxygenation parameters and Red blood cell characteristics
Time frame: Immediately after the venepuncture
Associations between sex, age, and genotype and the biomarkers of angiogenesis
Time frame: Immediately after the venepuncture
Association between hemoglobin, and HbF and biomarkers of angiogenesis
Time frame: Immediately after the venepuncture
Associations between whole blood viscosity and genotype
Time frame: Immediately after the venepuncture
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Nov 2024.
- Individual participant dataSharing planned: No
Related trials for Sickle Cell Retinopathy
Not yet recruitingPhase 3
Anti-VEGF Versus Prompt Laser or Observation for Proliferative Sickle Cell Retinopathy (ALPS)
Proliferative Sickle Cell Retinopathy
Active, not recruitingObservational study
Early Check: Expanded Screening in Newborns
Spinal Muscular Atrophy, Fragile X Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bart J Biemond, MD PhD principal investigator
Department of Hematology, Amsterdam UMC, Amsterdam, The Netherlands
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sickle Cell Retinopathy and Sickle Cell Disease, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Differences in Red blood cell characteristics (Oxygenscan) (time frame: Immediately after the venepuncture). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Nov 2024.